Company intelligence / Profile preview

The Ray

San Diego, California, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Ray Therapeutics is a clinical-stage biotechnology company focused on developing optogenetic gene therapies to restore vision in patients with blinding retinal diseases. The company's lead candidate, RTx-015, is designed to treat retinitis pigmentosa by making surviving retinal cells light-sensitive, bypassing damaged photoreceptors. Ray Therapeutics leverages a proprietary platform to engineer highly sensitive optogenetic proteins that can function under ambient light conditions without the need for external goggles. Headquartered in San Diego, the company is advancing a pipeline that also targets Stargardt disease and geographic atrophy.

Therapeutic areas: Ophthalmology
Modalities: Gene therapyOptogenetics
Industry: Biotech

Beyond the preview

Go deeper on The Ray.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on The Ray.

Explore the full profile